MPD: List measures where strain NZW/LacJ is an outlier

List measures where NZW/LacJ is an outlier

Click on pulldowns below to see NZW/LacJ means with summary statistic tooltips.
Within each pulldown, the "up" and "down" triangles indicate when this strain is an outlier.
You can also download all phenotypes for this strain and sort by Z score in Excel.

Sort/ Pick	Data set	Procedure / Protocol	Treatment	Phenotype Measure / Variable (click to view)	Panel	No. of Strains	Sex	Age	Sample Size (Avg)	Year
Ackert1:6	Ackert1	body size and weight	(none)	body weight [g] BW 25006 6mo 12mo 20mo	inbred	32	both		N=7	2008

Ackert1:26	Ackert1	DXA	(none)	total body area, head excluded [cm²] total_area 25026 6mo 12mo 20mo	inbred	32	both		N=7	2008

Ackert1:31	Ackert1	body size and weight	(none)	body mass index (BMI) [kg/m²] BMI 25031 6mo 12mo 20mo	inbred	32	both		N=7	2008

Ackert1:36	Ackert1	DXA	(none)	percent fat, head excluded [%] pctfat 25036 6mo 12mo 20mo	inbred	32	both		N=7	2008

Ackert1:41	Ackert1	DXA	(none)	total tissue mass, head excluded [g] TTM 25041 6mo 12mo 20mo	inbred	32	both		N=7	2008

Ackert1:51	Ackert1	DXA	(none)	weight of fat portion of body mass, head excluded [g] fatwt 25051 6mo 12mo 20mo	inbred	32	both		N=7	2008

Benoist1:3	Benoist1	immune cell quantification	(none)	percentage of splenic CD4 Treg cells that are CD25^hi [%] Treg_spl_CD25 25803	inbred	31	m	5-6wks	N=3	2007

Berndt1:1	Berndt1	ventilator	(none)	airway resistance (naive, untreated, H₂O pressure) [cm/mL/s] airway_res 34201	inbred	37	both	9-12wks	N=9	2010

Berndt2:8	Berndt2	plethysmography	methacholine	breath frequency [n/min] breath_freq 35108 saline 5 MCh 10 MCh 20 MCh response index	inbred	29	both	9-12wks	N=8	2010

Berndt2:14	Berndt2	plethysmography	methacholine	inspiratory phase [s] inspiratory 35114 saline 5 MCh 10 MCh 20 MCh response index	inbred	29	both	9-12wks	N=8	2010

Berndt2:28	Berndt2	plethysmography	methacholine	respiratory cycle [s] tot_respi 35128 saline 5 MCh 10 MCh 20 MCh response index	inbred	29	both	9-12wks	N=8	2010

Berndt2:34	Berndt2	plethysmography	methacholine	duty cycle [ratio] duty_cycle 35134 saline 5 MCh 10 MCh 20 MCh response index	inbred	29	both	9-12wks	N=8	2010

Brugnara1:1	Brugnara1	ion transport assessment	(none)	RBC sodium cation content (mmol/kg hemoglobin) [mmol/kg] sodium 47401	inbred	10	both	8wks	N=31	2013

Brugnara1:11	Brugnara1	complete blood count	(none)	reticulocyte differential (Retic; percentage of total RBC) [%] retic 47411	inbred	10	both	8wks	N=30	2013

CGDpheno1:21	CGDpheno1	complete blood count	(none)	mean platelet volume (MPV) [fL] MPV 31821	inbred w/CC8	72	both	11wks	N=7	2009

CGDpheno1:60	CGDpheno1	metabolic panel	(none)	total bilirubin (plasma TBIL) [µmol/L] TBIL 31860	inbred w/CC8	72	both	12wks	N=7	2009

Crowley1:7	Crowley1	inclined screen test	haloperidol	latency to move four paws, extrapyramidal side effects [s] latency 39407 day: 0 3 7 30 60 120	inbred w/CC8	27	m	9-28wks	N=6	2012

Crowley1:37	Crowley1	behavior observation	haloperidol	subtle chewing movements, 15 min test [n] subtlechew 39437 day: 0 30 60 120	inbred w/CC8	27	m	9-28wks	N=6	2012

Crowley1:41	Crowley1	behavior observation	haloperidol	jaw tremor duration, 15 min test [s] jawtremor 39441 day: 0 30 60 120	inbred w/CC8	27	m	9-28wks	N=6	2012

Harrill1:5	Harrill1	organ weights	isoniazid	liver weight [g] liver 39505 control isoniazid	inbred	34	f	8-10wks	N=4	2011

Harrill2:35	Harrill2	biomarker quantification	DB289	urine kidney injury molecule 1 (KIM-1) [pg] urine_KIM1 44135 control DB289 difference	inbred	33	f	6-8wks	N=4	2012

Harrill2:55	Harrill2	drug and metabolite quantification	DB289	kidney metabolite (DB75) concentration [µM] kidney_DB75 44155 control DB289	inbred	34	f	6-8wks	N=4	2012

Hawes1:19	Hawes1	ophthalmoscopy	(none)	retinal coloboma [frequency rate] ret_coloboma 26719	inbred w/CC7	40	both	6-7wks	N=10	2008

HMDPpheno1:3	HMDPpheno1	DXA	(none)	bone mineral density (BMD) of lumbar spine [g/cm²] BMD_spine 44603	HMDP w/par	96	m	16wks	N=9	2011

HMDPpheno2:1	HMDPpheno2	lipid profile	(none)	HDL cholesterol (plasma HDL) [mg/dL] HDL 46401	HMDP w/par	99	m	16wks	N=7	2010

HMDPpheno2:3	HMDPpheno2	lipid profile	(none)	unesterified cholesterol (plasma CHOL) [mg/dL] CHOL_un 46403	HMDP w/par	99	m	16wks	N=7	2010

HMDPpheno2:4	HMDPpheno2	lipid profile	(none)	total cholesterol (plasma CHOL) [mg/dL] CHOL_tot 46404	HMDP w/par	99	m	16wks	N=7	2010

Korstanje1:21	Korstanje1	urinalysis	(none)	albumin-creatinine ratio (urine ACR) [mg/g] ACR 29721 12mo 18mo 24mo	inbred	30	both		N=7	2008

Mills1:25	Mills1	chromosome instability assessment	(none)	reticulocytes with micronuclei [%] retic_micronucl 25225 6mo 12mo 20mo	inbred	30	both		N=5	2008

Paigen1:11	Paigen1	histopathology	high-fat diet	gallbladder, filaments (score: 0-4) [score] filaments 2911	inbred	43	both	15-19wks	N=8	2000

Paigen1:27	Paigen1	lipid profile	high-fat diet	hepatic cholesterol concentration (esterified per g liver) [mg] estHCC 2927	inbred	43	both	15-19wks	N=6	2000

Paigen4:1	Paigen4	lipid profile	(none)	HDL cholesterol (plasma) [mg/dL] HDLC 19701	inbred w/CC7	43	both	10wks	N=12	2002

Peters1:1	Peters1	complete blood count	(none)	white blood cell count (WBC; per volume x 10³) [n/µL] WBC 6201	inbred w/CC7	43	both	10wks	N=12	2001

Peters4:1	Peters4	complete blood count	(none)	white blood cell count (WBC; per volume x 10³) [n/µL] WBC 24301 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:5	Peters4	complete blood count	(none)	red blood cell count (RBC; per volume x 10⁶) [n/µL] RBC 24305 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:9	Peters4	complete blood count	(none)	neutrophil count (NEUT; units per volume x 10³) [n/µL] NEUT 24309 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:13	Peters4	complete blood count	(none)	lymphocyte count (LYM; units per volume x 10³) [n/µL] LYMPH 24313 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:17	Peters4	complete blood count	(none)	monocyte count (MONO; units per volume x 10³) [n/µL] MONO 24317 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:25	Peters4	complete blood count	(none)	basophil count (BASO; units per volume x 10³) [n/µL] BASO 24325 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:29	Peters4	complete blood count	(none)	large unstained cells count (LUC; units per volume x 10³) [n/µL] LUC 24329 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:45	Peters4	complete blood count	(none)	eosinophil differential (EOS; percentage of total WBC) [%] pctEOS 24345 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:53	Peters4	complete blood count	(none)	large unstained cells differential (LUC; percentage of total WBC) [%] pctLUC 24353 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:69	Peters4	complete blood count	(none)	mean RBC hemoglobin concentration (MCHC) [g/dL] MCHC 24369 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Peters4:89	Peters4	complete blood count	(none)	mean platelet volume (MPV) [fL] MPV 24389 6mo 12mo 18mo 24mo	inbred	30	both		N=7	2007

Petkova1:21	Petkova1	immune cell quantification	(none)	monocyte differential (MONO; percentage of total WBC) [%] MONO 24221 6mo 12mo 18mo 24mo	inbred	32	both		N=7	2007

Petkova1:41	Petkova1	immune cell quantification	(none)	CD4 T cells, effector memory, as percentage of total CD4 T cells [%] CD4_mem_effector 24241 6mo 12mo 18mo 24mo	inbred	32	both		N=8	2007

Rusyn2:75	Rusyn2	drug and metabolite quantification	trichloroethylene	trichloroacetic acid (serum TCA) [nmol/mL] TCA_tce 36175 time after treatment: 2h 8h 24h	inbred	15	m	7wks	N=3	2010

Rusyn5:1	Rusyn5	metabolic panel	high-fat diet and ethanol	serum alanine transaminase (ALT) [IU/L] ALT 43001 high-fat only high-fat and ethanol	inbred	14	m	8-14wks	N=3	2011

Rusyn5:11	Rusyn5	organ weights	high-fat diet and ethanol	liver weight as a percent of body weight [%] pctLW_BW 43011 high-fat only high-fat and ethanol	inbred	14	m	8-14wks	N=3	2011

Rusyn5:13	Rusyn5	histopathology	high-fat diet and ethanol	liver steatosis (0-4) [score] steatosis 43013 high-fat only high-fat and ethanol	inbred	14	m	8-14wks	N=3	2011

Rusyn5:19	Rusyn5	histopathology	high-fat diet and ethanol	total liver histopathology (0-8) [score] total_pathology 43019 high-fat only high-fat and ethanol	inbred	14	m	8-14wks	N=3	2011

Rusyn5:39	Rusyn5	metabolite quantification	high-fat diet and ethanol	ratio of liver SAM to SAH (SAM/SAH) [ratio] liver_SAM_SAH 43039 high-fat only high-fat and ethanol	inbred	14	m	8-14wks	N=3	2011

Rusyn5:46	Rusyn5	metabolite quantification	high-fat diet and ethanol	liver HSPA5 (formerly GRP78), protein expression relative to high-fat-only group [%] liver_HSPA5_hfe 43046	inbred	14	m	8-14wks	N=3	2011

Rusyn5:62	Rusyn5	RNA expression profiling	high-fat diet and ethanol	liver Ddit3 (formerly Chop), mRNA abundance relative to high-fat-only group [%] liver_Ddit3_hfe 43062	inbred	14	m	8-14wks	N=3	2011

Rusyn6:28	Rusyn6	RNA expression profiling	trichloroethylene	Cyp4a10, mRNA in liver, relative to control group [ratio] Cyp4a10_liver_tce 51228	inbred	7	m	6-7wks	N=3	2014

Rusyn6:55	Rusyn6	histopathology	trichloroethylene	kidney injury molecule 1 (KIM-1) positive proximal tubules [%] KIM1_kidney 51255 control TCE	inbred	7	m	6-7wks	N=4	2014

Willott1:2	Willott1	acoustic startle test	(none)	acoustic startle response (ASR) [amplitude] ASR 9102 sound pressure level: 70dB 80dB 90dB 100dB	inbred w/CC7	40	both	5-6wks	N=10	2002

Wiltshire3:1	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex ACTH, relative fluorescence intensity ACTH 38101 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:4	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex APOD, relative fluorescence intensity APOD 38104 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:7	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex BAG1, relative fluorescence intensity BAG1 38107 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:10	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex BDNF, relative fluorescence intensity BDNF 38110 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:13	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex CREB1 (CREB), relative fluorescence intensity CREB1 38113 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:16	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex FOS (c-fos), relative fluorescence intensity FOS 38116 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:19	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex FUT9, relative fluorescence intensity FUT9 38119 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:28	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GFAP, relative fluorescence intensity GFAP 38128 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:31	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GHRL, relative fluorescence intensity GHRL 38131 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:34	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GIRK3 (KCNJ9), relative fluorescence intensity GIRK3 38134 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:49	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex GSR, relative fluorescence intensity GSR 38149 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:61	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex P2RX7 (P2X7), relative fluorescence intensity P2RX7 38161 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:64	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex PAQR8, relative fluorescence intensity PAQR8 38164 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:70	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex PTH, relative fluorescence intensity PTH 38170 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:79	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex SLC6A2 (NET), relative fluorescence intensity SLC6A2 38179 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:82	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex SLC6A4 (SERT), relative fluorescence intensity SLC6A4 38182 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:88	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex TNF (TNFa), relative fluorescence intensity TNF 38188 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire3:91	Wiltshire3	biomarker quantification	fluoxetine	cerebral cortex VEGFA (VEGF), relative fluorescence intensity VEGFA 38191 control fluoxetine change index	inbred	30	m	10-11wks	N=3	2011

Wiltshire4:1	Wiltshire4	immune cell quantification	BEZ235	B cells, percent viability [%] Bcells_BEZ 52401 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	34	m	10wks	N=4	2015

Wiltshire4:61	Wiltshire4	immune cell quantification	selumetinib	B cells, percent viability [%] Bcells_Sel 52461 dose [µM]: control 0.046 0.137 1.235 11.1 100	inbred w/CC7	34	m	10wks	N=4	2015

Xing1:1	Xing1	ECG	(none)	heart rate [n/min] HR 24901 6mo 12mo 20mo	inbred	29	both		N=7	2008

Xing1:16	Xing1	ECG	(none)	interval RR [ms] RR 24916 6mo 12mo 20mo	inbred	29	both		N=7	2008

Yuan1:1	Yuan1	hormone quantification	(none)	insulin-like growth factor 1 (serum IGF-1) [ng/mL] IGF1 27001 6mo 12mo 18mo	inbred	33	both		N=7	2007

Yuan3:41	Yuan3	metabolic panel	(none)	potassium (serum K) [mmol/L] K 24441 6mo 12mo 18mo	inbred	32	both		N=7	2008

Zimmermann1:5	Zimmermann1	intake monitoring	(none)	food consumption, second day [g] food_intake 112168 during light during dark	inbred	30	both	7-15wks	N=11	2020

Zimmermann1:7	Zimmermann1	intake monitoring	(none)	water consumption, second day [mL] water_intake 112170 during light during dark	inbred	30	both	7-15wks	N=11	2020

Zimmermann1:15	Zimmermann1	monitoring system	(none)	respiratory exchange ratio (VCO2:VO2), second day [ratio] rer 112178 during light during dark	inbred	30	both	7-15wks	N=11	2020

List measures where NZW/LacJ is an outlier

Filter Table Results